Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at BTIG Research

by · The Markets Daily

BTIG Research assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX – Free Report) in a research note published on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $40.00 price target on the stock.

Separately, HC Wainwright assumed coverage on shares of Avalo Therapeutics in a report on Thursday, October 24th. They issued a “neutral” rating on the stock.

Check Out Our Latest Stock Analysis on AVTX

Avalo Therapeutics Stock Down 1.9 %

NASDAQ:AVTX opened at $8.91 on Thursday. The business’s 50-day moving average price is $11.13 and its 200 day moving average price is $10.73. Avalo Therapeutics has a 52-week low of $3.95 and a 52-week high of $34.46.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds have recently modified their holdings of AVTX. Affinity Asset Advisors LLC raised its holdings in Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after buying an additional 35,000 shares during the period. Logos Global Management LP acquired a new position in shares of Avalo Therapeutics in the second quarter worth about $6,722,000. Ikarian Capital LLC increased its position in shares of Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after acquiring an additional 915,629 shares in the last quarter. Finally, RA Capital Management L.P. acquired a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $9,186,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

(Get Free Report)

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

See Also